| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
PARIS, France—Keeping with its strategy to form lucrative partnerships in the global generic market and extend its pharmaceutical presence in emerging countries, sanofi-aventis, Europe's third-largest drugmaker, has crafted collaborative agreements with two generic pharmas south of the border—and secured a stronger foothold in China.

On April 2, the French drugmaker's subsidiary, sanofi-aventis Mexico, acquired Laboratorios Kendrick, and on April 9, sanofi-aventis signed an agreement for the acquisition of Medley, the third-largest pharmaceutical firm and top generic company in Brazil.

"The Kendrick acquisition represents an exceptional opportunity to accelerate our growth in the generic market in Mexico," says Jean-Marc Podin, vice president of media relations. "This will allow sanofi-aventis to accelerate sales growth and further extend its pharmaceutical portfolio in emerging markets. The deal (with Kendrick) has been signed and hence, benefits both parties. Sanofi-aventis proves once again its leadership and its commitment to offering quality medicines that satisfy the patients needs with one of the most comprehensive portfolios in the industry."

Mexico City-based generic drugmaker Laboratories Kendrick reported approximately $38 million in 2008 sales. Kendrick's portfolio incorporates more than 50 active ingredients in the areas of analgesics, antihistamines, anti-infectives, antirheumatics and cardiovascular and central nervous system drugs.

As a market leader in Mexico, sanofi-aventis Mexico has 2,500 employees and sales of approximately $784 million in 2008 in diabetes, oncology, thrombosis, pain and vaccines. In 2007, sanofi-aventis launched its own generic division in Mexico and has agreed to build a $131 million facility in Mexico to manufacture pandemic influenza vaccine.

Christopher Viehbacher, CEO of sanofi-aventis, caught the industry's attention last year when he made no secret about his intention to acquire generic pharmaceutical companies in the emerging markets. Shortly after being named in December to head up sanofi-aventis, Viehbacher said he planned to target small and mid-sized acquisitions to build up the company's global position in emerging markets, vaccines and biotechnology. However, the industry has speculated that sanofi-aventis is targeting acquisitions in emerging markets to help overcome generic competition to drugs that make up one-fifth of sanofi's revenue.

"As an industry, we've been too focused on rich countries," Viehbacher told Bloomberg in March. "If you are going to be a healthcare company, you have to be able to deal with healthcare concerns of patients around the world."

He then walked the walk last month when sanofi-aventis acquired Kendrick, then, one week later, Campinas, Brazil-based generic drugmaker Medley in a deal that values the company at $659 million. Medley has a generic drug portfolio of 127 products that accounted for 68 percent of its total revenues in 2008, and employs 1,550 collaborators, of which approximately 500 are in the sales force, LatinFinance.com reported.

The deal represents sanofi-aventis' strategy to grow in the generics area as patent expirations pressure growth, according to Edward Jones equities analyst Linda Bannister who speculated to LatinFinance.com that it is possible sanofi-aventis paid cash for Medley. The privately negotiated deal is expected to close in the second quarter.

The move reinforces sanofi-aventis' firm toehold as a top pharma in Brazil, with a total 12 percent market share, making sanofi-aventis the leading player in the field of generics in Brazil and Latin America.

Viehbacher also spoke of needing a presence in China, India and Africa since sanofi-aventis is currently "only treating a small fraction of patients in most of those countries. There is a huge opportunity there."

Sanofi-aventis is investing $90 million in China in order to produce its diabetes treatment, Lantus. The company also plans to expand its manufacturing facility in Beijing and build pre-filled production lines for Lantus SoloStar.

Said Viehbacher, "We remain convinced of the strategic importance of the Chinese market." The production of Lantus SoloStar, scheduled to start at the site in 2012, "will bring great benefits to the diabetes patients in China."

About the Author

Related Topics

Published In

Volume 5 - Issue 5 | May 2009

May 2009

May 2009 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue